अमूर्त
Insulin Used to Treat Hypoglycemia in Diabetes Patients
Meerab KHypoglycemia is a significant barrier to achieving insulin glycemic control in both type 1 and type 2 diabetes. Previously, it was difficult to accurately verify the prevalence of hypoglycemia in the clinical setting. available and requires real, high-quality data for accurate determination. prevalence of hypoglycemia in clinical practice. The Global Hypoglycemia Assessment Tool study was designed to evaluate the overall incidence of hypoglycemia in insulin-treated diabetics, and the results indicated that the overall prevalence of hypoglycaemia was hypoglycaemia. high blood pressure, with wide geographic variation. The International Operations HAT study retrospectively and prospectively evaluated the incidence of hypoglycemia in insulin-treated diabetics in Bangladesh, Colombia, Egypt, Indonesia, Philippines, Singapore, South Africa, Turkey and the United States. United Arab Emirates. In the prospective period, hypoglycemic events were reported by 97.4% of patients with type 1 diabetes and 95.3% of patients with type 2 diabetes, with an estimated rate of 6.86 events. per patient and per month for patients with type 1 diabetes and 2.37 PPPM events for patients with type 2 diabetes. These results represent the first patient-reported data set of hypoglycemia in the participating countries and confirm that hypoglycemia is underreported and more prevalent than what people believed in the past. Although the incidence of hypoglycemia varies among patients using different regimens, there are significant impacts on productivity and health care utilization following an episode of hypoglycemia.